Fispemifene

Drug Profile

Fispemifene

Alternative Names: HM-101

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Hormos Medical
  • Developer Apricus Biosciences
  • Class Alcohols; Osteoporosis therapies; Small molecules; Stilbenes
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Hypogonadism

Most Recent Events

  • 28 Mar 2016 Discontinued - Phase-I for Hypogonadism in Europe (PO)
  • 28 Mar 2016 Discontinued - Phase-II for Hypogonadism in USA (PO)
  • 28 Mar 2016 Top-line efficacy and adverse events data from a phase IIb trial in Hypogonadism released by Apricus Bioscience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top